Peptide Microarray Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Peptide Microarray Market is expected to register a CAGR of 5% during the forecast period.

Peptide microarrays and protein, the emerging tools for clinical assays and proteomics, are high-throughput methods that decide the function of proteins on a large scale. The development of therapeutics requires an accurate understanding of the role in the SARS-CoV-2 infection process and progression of COVID-19. The field of proteomics is equipped with the technologies that are required to help face this challenge.

In an article published in October 2020 in the Journal of Proteins and Proteomics, researchers have highlighted that developments in proteome technologies will not only accelerate progress in addressing the coronavirus pandemics but will also help to tackle the current COVID-19 crisis.

A peptide microarray is used to study the binding properties of protein-protein interaction that comprises thousands of peptides in distinct patterns that will be used as a high throughput screening tool in biomedical science.

Therefore the increasing burden of cancer and technological advancement are the major factors that are driving the studied market globally. Moreover, the rising prevalence of chronic diseases will further contribute to the peptide microarray market. For instance, according to the National Centre for Chronic Disease Prevention and Health Promotion (NCCDPHP), the United States has a population of about 330 million, of which 6 in 10 adults have chronic diseases each year. Thus, promoting diagnosis testing will propel the peptide microarray market.

Furthermore, rising molecular-based diagnostics techniques demand with the advancement in the technology of diagnostic testing dominant the peptide microarray market.

Key Market Trends

The Instrument Segment is Expected to Hold a Major Market Share in the Peptide Microarray Market

The instrument​ segment is expected to witness good growth in the market and is anticipated to show a similar trend over the forecast period, owing to technologically advanced peptide microarray products and various types of research in chronic disorders, such as cancer, autoimmune and infectious disease. For instance, PEPperPRIINT offers PEPperCHIP Standard Peptide Microarrays, which cover epitopes, antigens, and viral proteomics, and is widely used in various types of researches (allergen, cancer, and signature discovery).

Moreover, these are also used for antibody epitope mapping, biomarker discovery, immune monitoring, detection, and validation for protein interaction. For instance, JPT Peptide Technologies has a product PepStar Peptide Microarrays, which helps in enzyme profiling and identifies a substrate for orphan enzymes.

The research and development of peptide products are increasing as they are cost-effective, efficient, and have lower toxicity. These peptides play a major part in the COVID-19 related research. In 2020, PEPperPRINT launched the coronavirus research product PEPperCHIP Pan-Corona Spike Protein Microarray, which will give researchers access to serologically screen human coronavirus spike proteins in one assay. Hence, these factors will fuel the growth of the studied market.

North America is Expected to Hold a Significant Share in the Market and Expected to do the Same in the Forecast Period

North America is expected to dominate the global peptide microarray market due to the increasing healthcare expenditure and the presence of well-developed healthcare infrastructure. For instance, a report was published in July 2019 by MDPI wherein the Zika virus disease infected several territories in North America. The research was carried out using a peptide microarray to find the best candidates for T-B cells epitopes by immunoinformatic approach.

The growing chronic disease complexities are expected to enhance the demand for early diagnosis of the disease in the hospitals, thereby increasing the use of diagnostic capabilities, which is expected to boost the usage of peptide microarrays. According to Globocan 2020, the estimated incidence of new cancer cases was 2,281,658, and the number of deaths was 612,390 due to cancer in 2020 in the United States. The most common cancers in the United States were breast, lung, prostate, and colon (101,809). The high cancer burden will surge the demand for peptide microarray.

Moreover, rising molecular-based diagnostic techniques and increasing awareness among the population are also fueling the growth of the overall regional market.

Competitive Landscape

Some companies currently dominating the market include Merck KGaA, ProImmune Ltd, JPT Peptide Technologies, Terra Universal Inc., and Arrayit Corporation.

The market players are expanding their market position by adopting various strategies, such as acquisitions and mergers and research collaborations, while several others are introducing new products to increase their presence in the market. For instance, in 2020, JPT peptide technologies accelerated the development of a broad collection of SARS-CoV-2 PepMix Peptide Pools that would span the most relevant antigens to address cellular immunity. JPT developed a Pan-Coronavirus RepliTope Peptide Microarray spanning the entire SARS-CoV-2 proteome and selected antigens of MERS-CoV, Common Cold Coronaviruses, and SARS-CoV for profiling humoral immune responses.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support